The study, conducted by scientists at the University of Texas MD Anderson Cancer Center and the University of Florida, found that patients with advanced lung or skin cancer lived significantly longer if they received an mRNA-based COVID-19 vaccine within 100 days of starting immune checkpoint inhibitor therapy.

Researchers say the finding, though preliminary, points to a potential secondary benefit of mRNA vaccine technology: improving the body’s ability to fight tumors.

How mRNA Vaccines May Strengthen Cancer Treatment

The study’s lead author, Dr. Adam Grippin of MD Anderson, explained that the vaccines appeared to “activate immune cells throughout the body,” effectively priming them to recognize and attack cancer cells.

“The vaccine acts like a siren to activate immune cells,” Grippin said. “We’re sensitizing immune-resistant tumors to immune therapy.”

Unlike traditional vaccines that use weakened or inactivated viruses, mRNA vaccines deliver genetic instructions prompting the body’s cells to produce a harmless version of a viral protein. This process triggers a strong immune response — a mechanism scientists believe could also improve how the body targets tumor cells when combined with immunotherapy drugs.

A Promising Link Between mRNA Shots and Checkpoint Inhibitors

The team reviewed medical records from nearly 1,000 patients undergoing treatment for advanced cancers at MD Anderson. Those who had received a Pfizer or Moderna COVID-19 shot showed notably better outcomes compared to those who had not been vaccinated.

For lung cancer patients, vaccinated individuals were nearly twice as likely to survive three years after beginning treatment compared to their unvaccinated counterparts. Among melanoma patients, vaccinated individuals also showed longer survival times, though the exact median remains unclear because many were still alive when data analysis ended.

Notably, patients who received non-mRNA vaccines, such as influenza shots, did not experience similar benefits — suggesting that the mRNA component itself may play a unique role in enhancing immune response.

Scientific Reactions and Future Directions

Experts not involved in the study said the results add to growing evidence that mRNA technology could have broad applications beyond infectious diseases.

“This research offers a very good clue that maybe an off-the-shelf approach could work,” said Dr. Jeff Coller, an mRNA specialist at Johns Hopkins University. “What it shows is that mRNA medicines are continuing to surprise us in how beneficial they can be to human health.”

The MD Anderson and University of Florida team is now preparing a more extensive clinical trial to determine whether pairing mRNA vaccines with checkpoint inhibitors should become a standard treatment approach.

Checkpoint inhibitors work by disabling the “invisibility cloak” that allows some cancer cells to evade immune detection. However, not all patients respond to these drugs. Researchers hope mRNA vaccines could help stimulate immune systems in those whose cancers are resistant.

A Step Toward Future Cancer mRNA Vaccines

Scientists have long been developing personalized mRNA cancer vaccines, designed to teach the immune system to recognize the specific mutations unique to an individual’s tumor. The new findings suggest that even non-personalized mRNA vaccines, such as COVID-19 shots, may help generate broader immune activation beneficial to some cancer patients.

Grippin said his team first noticed this effect while developing tumor-targeting mRNA therapies in Florida. They observed that even vaccines without a custom-designed cancer target still appeared to boost immune activity against tumors — prompting them to investigate whether coronavirus vaccines might produce a similar outcome.

While researchers caution that the results do not apply to all cancers or all patients, the study could pave the way for new dual-use mRNA therapies that protect against infectious diseases while improving cancer outcomes.

Policy Context and Ongoing Debate

The findings come amid continued public debate over the role of mRNA vaccine technology. U.S. Health Secretary Robert F. Kennedy Jr. has expressed skepticism about the technology and recently announced a $500 million reduction in federal funding for some of its applications.

Nevertheless, researchers say the data from the Nature study reinforces the growing medical consensus that mRNA platforms may represent one of the most versatile tools in modern medicine.

As more research emerges, scientists hope to determine which cancer types and treatment combinations might benefit most from mRNA-based interventions — potentially transforming how the immune system is harnessed to fight both viruses and tumors.

Source: AP News – COVID-19 vaccines may help some cancer patients fight tumors

The post COVID-19 Vaccines May Boost Cancer Treatment Effectiveness, Study Finds appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

Breakthrough in Early Cancer Detection

The Galleri blood test, developed by U.S.-based pharmaceutical company Grail, can detect fragments of cancerous DNA circulating in the bloodstream. It is designed to identify cancers at an early stage, when treatment is more likely to be effective and potentially curative.

In a trial involving 25,000 adults in the United States and Canada over one year, nearly 1% of participants received a positive test result. Subsequent medical follow-up confirmed cancer in 62% of these cases. Lead researcher Dr. Nima Nabavizadeh, associate professor of radiation medicine at Oregon Health & Science University, stated that the findings could “fundamentally change” the approach to cancer screening.

High Accuracy and Early Detection

The trial demonstrated that the Galleri test correctly ruled out cancer in over 99% of participants who tested negative. More than half of detected cancers were identified at an early stage, increasing the likelihood of successful treatment.

When combined with conventional screening for breast, bowel, lung, and cervical cancers, the test increased the total number of detected cancers seven-fold. Notably, three-quarters of detected cases were cancers for which no routine screening currently exists, including ovarian, liver, stomach, bladder, and pancreatic cancers.

The test accurately identified the origin of cancer in approximately 90% of cases, providing crucial information for timely and targeted treatment.

Expert Perspectives on Potential Impact

Sir Harpal Kumar, president of biopharma at Grail, described the results as “very compelling,” emphasizing that most cancer deaths occur because cancers are detected too late. “The goal is to shift to earlier detection, when we can use treatments that are more effective and potentially curative,” he said on BBC Radio 4.

However, some experts caution that earlier detection does not automatically translate into reduced mortality. Clare Turnbull, professor of translational cancer genetics at The Institute of Cancer Research in London, stressed the need for randomized studies with mortality as a primary endpoint to confirm the test’s real-world benefits.

Naser Turabi of Cancer Research UK added that careful evaluation is required to avoid overdiagnosis of cancers that may never have caused harm. He noted that the UK National Screening Committee will play a central role in reviewing evidence before any NHS adoption.

Ongoing Research and NHS Trials

The topline results from the North American trial are set to be presented at the European Society for Medical Oncology congress in Berlin, though full peer-reviewed data have not yet been published.

In England, a three-year NHS study involving 140,000 participants is underway, with results expected next year. The NHS has indicated that, if the findings are favorable, the Galleri test could be expanded to an additional one million people, potentially reshaping national cancer screening strategies.

Future Implications for Cancer Care

The Galleri test represents a potential leap forward in early cancer detection, particularly for cancers lacking established screening programs. Experts highlight its promise in identifying diseases when interventions are most effective, potentially reducing the burden of late-stage diagnoses.

At the same time, further research is essential to understand the balance between early detection and overdiagnosis. Ongoing trials and rigorous peer-reviewed studies will be critical in determining how the test may be integrated into routine clinical practice.

Stay informed with JournosNews.com — your trusted source for verified global reporting and in-depth analysis. Follow us on Google News and BlueSky for real-time updates.

Source: BBC – Exciting results from blood test for 50 cancers

The post New Blood Test Shows Promise in Detecting Over 50 Types of Cancer Early appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

LIRA, Uganda — In a quiet village in northern Uganda, a sturdy bicycle leans against the wall of Lucy Abalo’s home. It’s not just hers — it belongs to the entire community.

Need a ride to the health center for a pregnancy check-up? Pick up HIV medication? Rush a child to the hospital? Just knock on Lucy’s door.

“The goodness about this bike,” she says, “is its availability to all.”

That rugged, steel-framed ride is called the Buffalo Bicycle — and it’s changing lives in places where the roads are rough and healthcare is far from reach.

Built for the Journey: The Buffalo Bicycle

The Buffalo Bicycle, designed by World Bicycle Relief, a Chicago-based nonprofit, is no ordinary bike. Built with heavy-duty steel and reinforced components, it’s made to handle the brutal terrain of rural Africa — from washed-out roads to narrow dirt tracks.

Retailing for around $200, it’s significantly more expensive than the average bicycle — and out of reach for most rural health workers who often work without a salary. But for those who have one, it’s a game-changer.

“It wasn’t easy at first,” Abalo recalls with a laugh. “I felt like I was learning to ride all over again.”

Delivering Healthcare on Two Wheels

Lucy Abalo is one of 331 community health extension workers (CHEWs) in Uganda who received a Buffalo Bicycle in a partnership between World Bicycle Relief and Uganda’s Ministry of Health. In her village, she’s known as a “village doctor” — a go-to for emergencies and health guidance.

She looks after nearly 8,000 people, visiting homes, triaging patients, and reporting to a government clinic 5 kilometers (3 miles) away — often multiple times a week. For health workers like her, transport isn’t a luxury — it’s a lifeline.

A recent study by World Bicycle Relief found that CHEWs with bicycles were able to double the number of households they reached each week and cut their travel time to clinics nearly in half.

“Mobility is not a luxury in healthcare,” said CEO Dave Neiswander. “It’s a lifeline.”

One Bike, Many Lives

The impact goes far beyond numbers.

One evening earlier this year, a 4-year-old boy in the village suffered a severe cut while playing. His parents were away. Abalo, bike at the ready, rushed him to a nearby facility where he briefly lost consciousness before being revived.

“That bike, not me, saved the life of that child,” she said. “If it hadn’t been there, I don’t know what would have happened.”

Her neighbor, Babra Akello, has borrowed the bicycle six times — the first time to attend an antenatal appointment. She praises both the bike and Abalo’s readiness to help.

A Broader Push for Better Health Access

Uganda, a country of 45 million, still faces major healthcare access challenges. Many rural facilities lack ambulances or even fuel, and health workers often travel long distances on foot.

Since 2023, Buffalo Bicycles Uganda has focused on two districts, including Lira, 274 miles north of the capital, Kampala. With growing demand, health officials like Diana Atwine, the Ministry of Health’s permanent secretary, are calling for more bikes across the country.

“Front-line health workers save an unknown number of lives each year,” Atwine said. “We must give them the tools they need.”

More Than a Bike

For rural Uganda, the Buffalo Bicycle is more than transportation — it’s an extension of the healthcare system itself. It’s a mobile clinic, a community ambulance, and in many cases, a second chance at life.

And in villages like Lucy Abalo’s, it’s always ready for the next knock at the door.

Source: AP News – Bikes tough enough for Uganda’s roads are helping health workers save lives

The post This Bike Could Save Your Life: Uganda’s Healthcare Heroes on Wheels appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

Lung cancer is often linked in our minds with smoking — but what happens when people who have never smoked start getting diagnosed more and more? The surprising rise of lung cancer among non-smokers is turning heads in the medical world, challenging old assumptions and raising important questions about causes, risks, and treatment.

Martha’s Story: A Wake-Up Call

Take Martha’s experience. At 59, she never considered herself a smoker — sure, she’d occasionally lit a cigarette at parties, but nothing regular. So when her cough changed and her mucus thickened, she thought it was just a flare-up from a rare lung disorder she already had. Doctors initially agreed it was nothing to worry about.

But after an X-ray revealed a shadow on her lung, things quickly escalated. A CT scan and bronchoscopy confirmed a tumour. Four months after she first mentioned symptoms, Martha was diagnosed with Stage IIIA lung cancer. The tumour had invaded nearby lymph nodes but hadn’t spread further.

“It was a total shock,” Martha says. And her story isn’t unique.

Lung Cancer Beyond Smoking: A Growing Global Concern

Lung cancer remains the world’s most common cancer and the deadliest, with around 2.5 million new cases and 1.8 million deaths in 2022 alone. While smoking still accounts for the majority of cases, smoking rates have dropped in many parts of the world over the last decades. At the same time, lung cancer diagnoses among people who have never smoked now make up 10 to 20% of cases — and that percentage is rising.

Dr. Andreas Wicki, an oncologist from the University Hospital Zurich, explains, “Lung cancer in never-smokers is emerging as a distinct disease, with unique molecular features that affect treatment and outcomes.” Interestingly, younger lung cancer patients—those in their 30s or 40s—are more likely to be non-smokers, and the cancer type tends to differ as well.

A Different Type of Lung Cancer

The kind of lung cancer common among smokers—squamous cell carcinoma—used to dominate until the mid-20th century. But in never-smokers, nearly all lung cancers are adenocarcinomas, which originate in mucus-producing cells.

The catch? Adenocarcinomas are often diagnosed late because small tumors don’t cause obvious symptoms. Persistent cough, chest pain, and breathlessness only show up once the tumour grows or spreads. “Because most people associate lung cancer with smoking, non-smokers may dismiss early warning signs, delaying diagnosis until advanced stages,” says Wicki.

Why Are Women More Affected?

Non-smoking women are more than twice as likely as men who never smoked to develop lung cancer. This may be linked to differences in lung anatomy, environmental exposures, and genetics. A key player is a mutation called EGFR, which is especially common in women and notably in Asian women.

Scientists suspect female hormones and genetic variants affecting estrogen metabolism might explain this higher incidence, though research is ongoing.

The Role of Genetics: Driver Mutations and Targeted Therapies

Cancer cells in non-smokers often carry “driver mutations” that fuel tumour growth. EGFR mutations are the best-known example. Once these mutations were identified, drug companies developed targeted therapies—EGFR inhibitors—that block the mutant protein’s activity.

“About 20 years ago, these drugs showed great promise,” Wicki says. “Many patients responded well, but resistance often developed, leading to relapse.” Newer generations of these drugs are now improving survival, with some patients living more than 10 years after diagnosis—an incredible leap from the less-than-12-month survival rates seen two decades ago.

What’s Causing Lung Cancer in Non-Smokers?

Without smoking as a cause, what else is driving lung cancer? Experts point to a mix of environmental and genetic factors:

• Radon exposure and second-hand smoke
• Indoor air pollution from cooking fumes and burning wood or coal, especially in poorly ventilated homes
• Outdoor air pollution, which is now recognized as the second leading cause of lung cancer worldwide after smoking

Air pollution—specifically tiny particles called PM2.5 found in vehicle exhaust and fossil fuel smoke—has been linked to lung cancer, particularly among those with EGFR mutations.

How Air Pollution May Trigger Lung Cancer

New research from the Francis Crick Institute in London sheds light on how air pollution might kickstart lung cancer in non-smokers carrying the EGFR mutation. Instead of directly mutating DNA like cigarette smoke, PM2.5 particles activate immune cells called macrophages. These cells release signals that “wake up” dormant mutant cells in the lungs, pushing them to grow into tumors.

This discovery opens exciting possibilities for new ways to prevent lung cancer by targeting the lung environment, not just the cancer cells themselves.

The Bigger Picture: Air Pollution’s Growing Impact

Air pollution’s connection to lung cancer isn’t new—it was mentioned as a possible cause as early as 1950. Yet for decades, anti-smoking policies dominated lung cancer prevention.

Today, 99% of the world’s population lives in areas exceeding the World Health Organization’s air quality guidelines. Rising pollution in places like India and China means the lung cancer burden from environmental factors may grow.

In the US, wildfires are causing spikes in PM2.5 levels, linked to increased lung cancer cases. Experts agree that shifting away from fossil fuels is critical not only for climate change but also for lung health.

Looking Ahead: Changing Perceptions and Hope

As treatments improve, lung cancer in never-smokers is becoming more manageable, challenging the stereotype that lung cancer is a smoker’s disease or a death sentence.

Martha, now almost three years post-diagnosis, takes an EGFR inhibitor. It’s not easy—side effects like fatigue and skin issues make daily life challenging—but the drug works. “The fatalistic view of lung cancer is changing, and that’s a hopeful sign,” she says.

With ongoing research and growing awareness of environmental risks, the future may hold better prevention and longer survival for those diagnosed with this mysterious form of lung cancer.

Source: BBC – The mystery rise of lung cancer in non-smokers

The post The Rise of Lung Cancer in Non-Smokers: What You Need to Know appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

In a major step forward for women’s health, the U.S. Food and Drug Administration has approved the Teal Wand — the first at-home device for cervical cancer screening. This breakthrough means women may soon be able to skip the speculum and stirrups and screen for cervical cancer from the comfort of their own home.

A Game-Changer for Cervical Cancer Screening

Developed by Teal Health, the Teal Wand allows users to collect their own vaginal samples at home and send them to a lab for HPV testing. The device will be included in Teal Health’s upcoming at-home screening kit, which will be available by prescription starting this June — launching first in California, with plans to expand across the U.S.

“This is the same test, with the same accuracy as in-clinic collection — but now you can do it from home,” said Teal Health CEO Kara Egan. “It gives women more options, especially through telehealth, and increases access to essential care.”

How It Works

Here’s how the process unfolds:

1. Request a Kit: Patients begin by visiting Teal Health’s website to request a kit.
2. Telehealth Visit: A quick consultation with a provider results in a prescription.
3. At-Home Collection: The patient uses the Teal Wand to collect a sample in private.
4. Mail to Lab: The sample is sent to a lab and analyzed using Roche’s HPV testing platform.
5. Results & Follow-Up: Results are reviewed by a clinician and shared with the patient. If needed, follow-up care is arranged.

Why It Matters

HPV (human papillomavirus) is the leading cause of cervical cancer, and early detection is critical. Yet millions of people in the U.S. are not up to date on their screenings. According to the CDC, about one in four adults fall behind on cervical cancer screening guidelines.

“This new test could be a game-changer,” said Dr. Ami Vaidya, co-chief of gynecologic oncology at Hackensack University Medical Center. “Some women avoid Pap smears due to discomfort or fear. Giving them a reliable at-home option could increase regular screenings, especially for those without easy access to a doctor.”

Support from Experts

The American Cancer Society praised the FDA’s decision.
“Most cervical cancers are found in people who were never screened or haven’t been screened recently,” said Dr. William Dahut, the organization’s chief scientific officer. “This at-home test adds a powerful tool in our fight against a potentially deadly disease.”

Understanding Cervical Cancer Screening

Cervical cancer screening typically involves:

• Pap tests (cytology): Detects abnormal cell changes in the cervix.
• HPV testing: Checks for the virus that can cause those changes.

The U.S. Preventive Services Task Force recommends:

• Women ages 21–29: Pap test every 3 years.
• Women ages 30–65: Either Pap test every 3 years, HPV test every 5 years, or both tests every 5 years.

Teal Health’s self-collection kit is designed to match the accuracy of these traditional methods while removing barriers like scheduling appointments or facing uncomfortable procedures.

What’s Next?

Teal Health is currently in talks with insurance providers to cover the cost of the kit. For those without insurance, pricing will be announced soon. A waitlist is already open on the company’s website.

With FDA approval now in place, the future of cervical cancer screening is looking more accessible — and more comfortable — than ever.

Source: CNN – FDA approves first cervical cancer screening device that can be used at home, company says

The post FDA Approves First At-Home Test for Cervical Cancer Screening appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

A Breakthrough in Pain Relief

The U.S. Food and Drug Administration (FDA) has approved suzetrigine, the first new type of pain reliever in over two decades. This non-opioid medication, developed by Vertex Pharmaceuticals, provides an alternative for managing acute pain without the risk of addiction.

Marketed under the brand name Journavx, suzetrigine is a 50-milligram prescription pill taken every 12 hours after an initial larger dose.

Why This Approval Matters

Dr. Jacqueline Corrigan-Curay, acting director of the FDA’s Center for Drug Evaluation and Research, emphasized the importance of this approval:

“A new non-opioid analgesic for acute pain offers an opportunity to mitigate certain risks associated with using opioids and provides patients with another treatment option.”

This move aligns with the FDA’s efforts to combat the opioid crisis by promoting safer pain management alternatives.

How Suzetrigine Works

Unlike opioids, which dull pain by acting on the brain, suzetrigine targets pain at its source by blocking pain-signaling nerves before they can transmit pain messages to the brain.

Dr. Sergio Bergese, an anesthesiologist at Stony Brook University, explained:

“This drug interrupts the pain pathway so that even though the tissue injury exists, the brain doesn’t recognize it as pain.”

Crucially, suzetrigine does not produce euphoria or a “high,” reducing the risk of dependence and addiction.

Inspired by a Rare Genetic Mutation

The breakthrough behind suzetrigine stemmed from a Pakistani family with a rare genetic condition. Members of this family could walk on hot coals without experiencing pain due to a mutation in their sodium channels—the same channels responsible for transmitting pain signals.

This discovery led researchers to develop suzetrigine, which works by blocking a specific sodium channel that only carries pain signals, leaving other sensations like heat and touch unaffected.

Dr. Stephen Waxman of Yale University described it as a major advancement:

“This provides proof of concept that a sodium-channel blocker can reduce pain in humans, opening the door for even more effective medications in the future.”

How Effective Is Suzetrigine?

Suzetrigine has been tested in multiple clinical trials, including:

1. Post-Surgical Pain Relief
   • In two studies with 600 participants, suzetrigine reduced pain as effectively as Vicodin (a combination of acetaminophen and the opioid hydrocodone).
   • Participants reported about a 50% reduction in pain levels.
2. Chronic Pain & Sciatica
   • A smaller study on sciatica patients showed mixed results, with pain reduction similar to a placebo.
   • Vertex Pharmaceuticals insists ongoing research suggests the drug may work for other types of chronic pain, including diabetic neuropathy.

Dr. Kimberley Mauer, an anesthesiologist at Oregon Health & Science University, highlighted the significance:

“The more options we have, the better we’re able to treat each and every patient.”

Availability & Cost

• Pricing: $15.50 per 50-mg pill
• Insurance Coverage: Still uncertain; patient assistance programs will be available

Dr. Mauer cautioned that insurance coverage could impact access:

“It might limit some patients from getting it. We’ll have to wait and see how it plays out in the market.”

The Future of Pain Management

Suzetrigine represents a significant step toward safer pain relief options, particularly as the medical community seeks alternatives to opioids.

With this approval, researchers hope to develop even better non-opioid painkillers, offering relief without the risks of addiction.

Source

The post New Non-Opioid Pain Medication Gets FDA Approval appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

Venomous animals are often associated with creatures like snakes, scorpions, and spiders. But did you know that some caterpillars also carry powerful venom capable of injuring or even killing a person? This surprising fact highlights the potential of venomous caterpillars as an untapped source of medical breakthroughs.

While the idea of venomous caterpillars might seem unusual, scientists are increasingly interested in the valuable compounds hidden within their toxic secretions. These compounds could lead to the development of new life-saving drugs.

The Hidden Potential of Caterpillar Venoms

Caterpillars, the larval form of butterflies and moths, are part of a larger group of venomous animals that remain largely unexplored. According to Andrew Walker, an evolutionary biologist at the University of Queensland, “There’s a lot of foundational work to do, but we’ll definitely see useful compounds from caterpillar venoms in the future.”

Venoms, which are toxins deliberately injected into another organism, are different from poisons that passively reside within an animal. In nature, venoms have evolved over millions of years to target specific biological processes in other creatures. This makes them highly efficient and refined agents, which could be invaluable in drug discovery.

Venoms: Nature’s Molecular Masterpieces

The diversity of venomous species in the animal kingdom is remarkable. “No two species have the same venom arsenal,” says Mandë Holford, a venom scientist at Hunter College and the American Museum of Natural History. Venoms are often complex mixtures of compounds, with some containing over 100 different molecules. By studying these venoms, researchers can identify powerful new drug candidates.

“Venoms have been tested in nature over millions of years, and we know they work,” explains Holford. In contrast, designing similar molecules in the lab often yields lower success rates. As a result, venoms from various species, including caterpillars, may offer a better starting point for drug development.

A Vast, Untapped Resource

Despite the known benefits of studying venoms from snakes, scorpions, and spiders, many venomous species, including caterpillars, remain largely under-researched. “We have a huge wealth of knowledge about snake venoms and scorpion venoms,” says Nicholas Casewell, a venom biologist at the Liverpool School of Tropical Medicine. “But there are many groups of venomous animals that haven’t been studied in depth yet.”

Walker, who wrote about venomous Lepidoptera in the 2025 Annual Review of Entomology, emphasizes that caterpillars are a prime example. Although only about 2% of caterpillar species are venomous, they are spread across the lepidopteran evolutionary tree, meaning venom has likely evolved multiple times within this group. This diversity could lead to a wide array of unique, potent compounds.

The Danger of Venomous Caterpillars

While most caterpillars are harmless, a few venomous species pose significant health risks. In South America, the genus Lonomia contains caterpillars whose venom interferes with blood clotting, potentially causing death. Other species can trigger chronic inflammation or even cause miscarriages in horses.

Although these dangerous caterpillars don’t pose a regular threat to human life like snakes or scorpions, their venom is still a serious public health concern in some regions. Researchers are studying Lonomia venom to better understand its effects and develop antivenoms.

Beyond Harm: The Medical Promise of Caterpillar Venoms

While many caterpillar venoms are still relatively unstudied, some may offer unexpected medical benefits. For instance, the pain caused by caterpillar stings could be used to investigate pain pathways and receptors in the human body. By exploring these pain mechanisms, researchers could eventually develop new pain-relieving drugs.

Though no new drugs have emerged yet from caterpillar venom research, other animal venoms have already yielded groundbreaking therapies. Snake venom, for example, has inspired blood-pressure and anti-clotting medications, while a molecule extracted from the venom of the Gila monster contributed to the creation of the blockbuster drug semaglutide (brand names: Ozempic, Wegovy).

The Future of Venom Research

Thanks to advances in molecular biology and bioinformatics, researching animal venoms, including those from caterpillars, is becoming increasingly accessible. “Venoms are like a treasure trove just waiting for us to understand,” says Casewell. As scientists continue to explore these venoms, we can expect new breakthroughs in drug development, possibly transforming the treatment of various diseases.

In summary, venomous caterpillars—often overlooked—are an exciting, untapped source of potentially life-saving drugs. Their unique venoms could lead to new treatments for pain, blood clotting disorders, and more. By further studying these fascinating creatures, scientists are opening the door to a future of medical advancements that could benefit millions.

Source

The post How Venomous Caterpillars Could Help Save Lives with New Medicines appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

Chinese scientists have made significant progress in fertility research by using stem cell transplantation to extend the reproductive lifespan in female monkeys. This breakthrough could provide new options for women struggling to conceive, especially as the average age for having children continues to rise.

The study, conducted by researchers from the Chinese Academy of Sciences and published in Cell Discovery, addresses the issue of ovarian aging, which naturally affects female fertility. As the ovaries age, they produce fewer eggs and hormones, leading to menopause and related health issues. Currently, there is no effective treatment to fully restore ovarian function.

Stem cells have shown promise in treating premature ovarian aging, so researchers investigated whether these treatments could benefit naturally aging ovaries. In the study, they transplanted M-cells—stem cells derived from human embryonic cells with strong immune and anti-inflammatory properties—into the ovaries of aging crab-eating macaques, a type of monkey with a reproductive aging pattern similar to humans.

The results were promising. The treated monkeys showed improved hormone levels, more active ovarian follicles, reduced ovarian fibrosis, and even healthier overall reproductive functions. One monkey even conceived and gave birth, highlighting the treatment’s potential.

With the average age of first-time mothers rising—27 in the United States, nearly 29 in Australia, and over 32 in South Korea—more women are experiencing fertility challenges as ovarian function begins to decline around their late 30s to mid-40s. In China, where the average age for first-time mothers is now over 27, regions like Shanghai see averages above 30.

Current treatments, like hormone replacement therapy, can help ease menopausal symptoms but carry risks such as heart disease, stroke, and breast cancer. Researchers aim to find safer, more effective treatments, especially given that ovarian aging can lead to serious conditions, including osteoporosis, cardiovascular disease, and neurodegenerative disorders.

The study also examined ovarian tissue samples from Chinese women in various age ranges. Findings showed a sharp decline in primordial follicle reserves by age 40, with reserves nearly exhausted by early 50s. But these remaining follicles could still potentially grow, supporting the idea of extending reproductive lifespan.

M-cell transplantation could be a safer and more effective approach to delay ovarian aging, as none of the treated monkeys showed signs of inflammation or other serious side effects. In comparison to untreated monkeys, the transplanted group showed improved hormone levels, follicle development, reduced fibrosis, and lower DNA damage.

The research team concluded that “M-cell transplantation is a feasible clinical strategy to alleviate physiological ovarian aging and extend fertility lifespan,” offering a new direction in fertility treatment that could improve quality of life for many women.

Source

Full Video

The post Chinese Scientists Discover Stem Cell Treatment to Combat Ovarian Aging appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.